Analyst Research
| Report Title | Price |
|---|---|
|
Provider: Thomson Reuters Stock Report
|
$25.00
|
|
Provider: S&P Capital IQ Quantitative Report
|
$69.00
|
|
Provider: Pechala's Reports
|
$15.00
|
|
Provider: Reuters Investment Profile
|
$20.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
TearLab Corp Announces Proposed Public Offering Of Common Stock
TearLab Corp announced its intention to offer, subject to market and other conditions, shares of its common stock in an underwritten public offering. TearLab also expects to grant the underwriter a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the public offering to cover over-allotments, if any. The proceeds of the offering will be used for working capital and general corporate purposes. Craig-Hallum Capital Group LLC is acting as the sole book-running manager for the offering.
Latest Key Developments in Medical
- CryoLife Inc Receives Conditional IDE Approval To Begin Clinical Trials For PerClot In The U.S.
- Essilor International SA Acquires Eight Businesses
- MIT Capital Inc Proposes To Acquire Meade Instruments Corp For $3.65 Per Share In Cash
- FDA Grants Prostate IDE Approval For Angiodynamics Inc's NanoKnife System
- Share this
- Link this
- Digg this
Follow Reuters